Machine translation by Google Translate, loaded only when you choose a language. See the Cookie policy and Help.
Shardhan Corporate Consultants LLPMarket entry, tax, compliance and managed finance services · since 2010
From pharmaceutical subsidiary formation and regulatory strategy to clinical-trial transfer pricing and medical-device GST classification, we support healthcare companies entering and growing in India.
India is the world's largest producer of generic medicines and a fast-growing medical-devices market, with manufacturing cost advantages, a large patient population and a skilled scientific workforce.
The sector works under several regulators, including CDSCO (Central Drugs Standard Control Organisation), the Ministry of Health and state drug controllers, and the Drugs and Cosmetics Act, alongside the usual FEMA, tax and corporate compliance.
Foreign companies usually set up a wholly owned private limited company for manufacturing, distribution or R&D. We handle incorporation and FDI compliance, and advise on how the corporate structure interacts with licences under the Drugs and Cosmetics Act.
Contract research, clinical-trial agreements and R&D cost-sharing with overseas affiliates must be priced at arm's length. We benchmark R&D services, IP licensing and data-sharing arrangements and defend positions in TP assessments.
Rates vary widely: many life-saving medicines are at 5% or nil, while devices attract rates from 5% to 18% depending on HS classification. Healthcare services are largely exempt, but digital health, diagnostics and medical-tourism facilitation can be complex. We manage classification, registration and filings.
Healthcare FDI has specific conditions, which differ for greenfield and brownfield pharmaceutical investment; brownfield acquisitions above the automatic-route limit need Government approval. We advise across hospitals, diagnostics, pharma and devices and handle FC-GPR, APR and capital-account reporting.
Digital-health startups, diagnostic chains and medtech companies need finance leadership that understands capex-heavy infrastructure, regulated pricing and insurance reimbursement cycles. We provide monthly financial management, board reporting and investor-grade compliance.
Tell us about your plans for India. We reply with a scope and fee proposal under a formal engagement letter.